Literature DB >> 9764136

Prolonged recovery in first-episode psychosis.

J Edwards1, D Maude, P D McGorry, S M Harrigan, J T Cocks.   

Abstract

BACKGROUND: Early identification and specialised treatment of individuals with enduring positive symptoms may assist in alleviating symptoms and has the potential to change the course of illness.
METHOD: Prevalence and descriptive data on enduring positive symptoms in two first-episode samples are outlined. Attempts to incorporate the focus of early intervention for persisting psychosis into routine clinical care of individuals with first-episode psychosis are described.
RESULTS: Of the 227 individuals with first-episode psychosis who were assessed using the Brief Psychiatric Rating Scale at 3/6 months and 12 months following initial stabilisation (from a total sample of 347), 6.6% experienced enduring positive symptoms at all three time points. When the analysis was restricted to schizophrenia, schizophreniform and schizoaffective disorders (n = 158) the percentage increased to 8.9%. These patients had significantly longer mean duration of untreated psychosis prior to initiation of treatment and, at 12-month follow-up, significantly higher depression and poorer psychosocial functioning.
CONCLUSIONS: The association of untreated psychosis with treatment resistance supports the argument for early intervention as soon as possible following the onset of psychotic symptoms.

Entities:  

Mesh:

Year:  1998        PMID: 9764136

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  11 in total

Review 1.  Rationale for the study of early intervention.

Authors:  R J Wyatt; I Henter
Journal:  Schizophr Res       Date:  2001-08-01       Impact factor: 4.939

2.  A qualitative research study of the evolution of symptoms in individuals identified as prodromal to psychosis.

Authors:  Cheryl Corcoran; Larry Davidson; Rachel Sills-Shahar; Connie Nickou; Dolores Malaspina; Tandy Miller; Thomas McGlashan
Journal:  Psychiatr Q       Date:  2003

3.  Prodromal interventions for schizophrenia vulnerability: the risks of being "at risk".

Authors:  Cheryl Corcoran; Dolores Malaspina; Laura Hercher
Journal:  Schizophr Res       Date:  2005-03-01       Impact factor: 4.939

4.  Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis.

Authors:  Andrew T Olagunju; Scott R Clark; Bernhard T Baune
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

Review 5.  Clozapine as a Model for Antipsychotic Development.

Authors:  Frederick C Nucifora; Marina Mihaljevic; Brian J Lee; Akira Sawa
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

6.  Cannabis and Psychosis: What Can Daily Diaries Tell Us About Who is Vulnerable?

Authors:  David Kimhy; Kelly Durbin; Cheryl M Corcoran
Journal:  Prim psychiatry       Date:  2009

7.  Do antipsychotics limit disability in schizophrenia? A naturalistic comparative study in the community.

Authors:  Jagadisha Thirthalli; Basappa K Venkatesh; Magadi N Naveen; Ganesan Venkatasubramanian; Udupi Arunachala; Kengeri V Kishore Kumar; Bangalore N Gangadhar
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

8.  Randomized Controlled Trial of Clozapine and CBT for First-Episode Psychosis with Enduring Positive Symptoms: A Pilot Study.

Authors:  J Edwards; J Cocks; P Burnett; D Maud; L Wong; H P Yuen; S M Harrigan; T Herrman-Doig; B Murphy; D Wade; P D McGorry
Journal:  Schizophr Res Treatment       Date:  2011-03-30

9.  Treatment-refractory schizophrenia.

Authors:  Asaf Caspi; Michael Davidson; Carol A Tamminga
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

10.  Use of an Online Clinical Process Support System as an Aid to Identification and Management of Developmental and Mental Health Problems.

Authors:  Barbara J Howard; Raymond Sturner
Journal:  Curr Dev Disord Rep       Date:  2017-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.